Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Morgan Stanley comments on Coherent (COHR.US) Q1 financial report: not perfect but "good enough", the real highlight is the 20 billions USD long-term contract

Morgan Stanley comments on Coherent (COHR.US) Q1 financial report: not perfect but "good enough", the real highlight is the 20 billions USD long-term contract

智通财经智通财经2026/11/06 07:16
Show original

Morgan Stanley has released its commentary on Coherent (COHR.US) following the company’s fiscal Q1 2027 earnings report, maintaining an "Equal-weight" rating and a target price of $325.

According to information from Zhihui Finance APP, on November 5, Morgan Stanley released its review of Coherent’s (COHR.US) Q1 FY2027 financial report, maintaining an "Equal-weight" rating and a $325 target price. The report noted that both quarterly revenue and earnings exceeded expectations and, for the first time, clarified the potential scale of a $20 billion Near Packaging Optics (NPO) long-term agreement starting from 2028 over five years. However, the climb in gross margin continues to lag behind peers, with real profit margin flexibility expected in 2028. Morgan Stanley also significantly raised its earnings forecasts for FY2027 to FY2029.

Performance itself: “Not a perfect score, but enough to impress the judges”

Coherent reported Q1 revenue of $2.37 billion, surpassing expectations of $2.302 billion; non-GAAP gross margin was 40.6%, and earnings per share reached $2.09, both better than expected. AI remains the main driver: data center and communications segment revenue increased 79% year-on-year, accounting for 82% of total revenue, while data center interconnect (DCI) revenue broke $200 million in a single quarter. Management expects FY2027 revenue growth to exceed 60%, and for FY2028, to reach $4 billion per quarter. Since the share price had already corrected sharply over the past week and annual gains have essentially been erased, Morgan Stanley believes negative factors were priced in early and expects a muted market response after the results.

The most incremental news: A potential $20 billion long-term agreement

The true highlight of the report is order visibility for 2028 and beyond. The previously mentioned new NPO long-term agreement (LTA) has now been quantified—starting from 2028 for five years with a potential scale of $20 billion. Currently, the company holds more than 10 CPO (Co-Packaged Optics) projects, more than 10 NPO projects, and over 5 chip-to-chip interconnect projects. Scale-out CPO revenue is expected to exceed $100 million in Q3 and surpass $250 million by the end of 2027. As for the market debate over whether the 400-milliwatt continuous wave laser can be integrated into Nvidia’s complete machine solutions—this certification is not officially confirmed, and the company maintains that related revenues will be realized beginning in 2027; however, Morgan Stanley has not included this in its base-case logic.

Gross margin: Investors’ “sore spot”, management’s “postdated check”

The slow climb in gross margin relative to peers is the main criticism Coherent faces. Management has issued a “postdated check”: achieving over 45% gross margin by 2028. Morgan Stanley makes a clear distinction: most improvements will come in 2028 as CPO revenue scales up. On the supply chain side, there has been better-than-expected progress—indium phosphide (InP) capacity doubled year-on-year in the first quarter, ahead of schedule by a quarter. Based on this, Morgan Stanley raised its FY2027/2028/2029 EPS forecasts to $10.07/$15.19/$18.98 (up +9%/+14%/+13%), and the FY2028 forecast is nearly double year-to-date.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56

Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.

After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.

智通财经•2026/11/06 07:53

Hong Kong live music service provider Guitar Group applies for US IPO, aiming to raise $31 million

Guitar Group, a provider of music performance events, guitar-making workshops, and guitar repair services, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, seeking to raise up to $31 million through an initial public offering (IPO).

智通财经•2026/11/06 07:50